Vitamin d derivatives

Vitamin D2 derivatives
Vitamin D3 derivatives

 

 

Vitamin D2 derivatives 18g Calcifediol BP, 25g;Calcitriol,EPVII,5g;Alfacalcidol,>98% are in-stock
511-28-4
97.0%-103.0%
22-Dihydroergocalciferol;22,23-Dihydroergocalciferol,Vitamin D4
Synonyms
22-Dihydroergocalciferol;22,23-Dihydroergocalciferol
Systematic Name
9,10-Secoergosta-5(Z),7(E),10(19)-trien-3beta-ol 
Molecular Formula
C28H46O
Molecular Weight
398.6704
Appearance
White to off-white powder
Residual substance
Any single impurity: N.M.T:0.1%
131918-61-1
21343-40-8
54573-75-0
Vitamin D3 derivatives
41294-56-8
97.0%-103.0%
63283-36-3
BP2007 &EPIV
32222-06-3
EPV
147657-22-5
103909-75-7
N/A
Maxacalcitol imurity
131875-08-6
104121-92-8
N/A
Eldecalcitol impurity
Pre-Eldecalcitol [Impurity]
N/A
Eldecalcitol impurity
N/A
Eldecalcitol impurity
151546-09-7
Eldecalcitol intermediate
134404-52-7
55721-11-4
199798-84-0
163217-09-2
93129-94-3
83805-11-2
Atocalcitol
302904-82-1
 
25-hydroxycholecalciferol
63283-36-3
 
Custom synthesis for VD derivatives
[1]:Active Vitamin D derivatives
See above APIs list
[2]:Vitamin D intermediates for API.
See Pro-eldecaltitol (n-4 step) Eldecalcitol intermediate
[3]:Vitamin D impurities for API
Patent Disclaimer
PD1
Products protected by valid patents are not offered for sale in jurisdictions where the sale of such products constitutes a patent infringement. The current list only reflects the products and technologies that are available, under development: note that some products may be developed or produced for internal and experimental uses with no commercal aim.
PD2
Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and development quantities.
PD3
the buyer assumes responsibility of all patent considerations in the use of
Lano ’s Pharmaceutical Co.,Ltd product(s).
PD4
R&D use in accordance with (1) 35 USC 271(e)+A13(1) in the U.S.; (2) Section 69.1 of Japanese Patent Law in Japan; (3) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (4) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (5) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (6) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (7) such similar laws and rules as may apply in various other countries.